Top

International Journal of Clinical Oncology

Published in:

27-05-2023 | Cancer Biomarker | Original Article

Predictive value of circulating tumor cell counts during the treatment of cancer: interactions with the blood microenvironment

Authors: Liu Yang, Xiaojiao Zeng, Gui Yang, Yirong Li, Yunbao Pan

Published in: International Journal of Clinical Oncology | Issue 8/2023

Abstract

Objective

This study aimed to evaluate the prognostic value of circulating tumor cell (CTC) in tumor patients during treatment.

Methods

This study retrospectively analyzed clinical data obtained from 174 cancer patients during treatment. The relationship between the CTC counts and clinicopathological variables was analyzed. A ROC curve was applied to determine the optimal cut-off values and assess the predictive ability of the prognostic indicators. The overall survival (OS) for different prognostic factors was calculated using the Kaplan–Meier method, and the difference between the survival curves was then compared using the log-rank test. Cox regression model was used to investigate the effect of independent factors on patients’ survival.

Results

The CTC-positive rate was positively correlated with the clinicopathological variables of TNM stage, tumor differentiation, serum CEA level, and ki-67%. In the differential analysis of hematological microenvironment parameters in CTC-positive and CTC-negative samples, the complete blood count, blood biological chemistry, tumor markers (CEA, CA19-9, CA72-4), and lymphocyte subpopulation were statistically significant. The results of the ROC curve analysis indicated that the serum CEA level was the best diagnostic indicator to discriminate the CTC count in tumor patients. Additionally, the results of the univariate and multivariate analyses of OS in relation to clinical variables revealed that the CTC counts were an independent prognostic factor for unfavorable OS.

Conclusion

The CTC counts in patients with tumors undergoing treatment were significantly correlated with hematological microenvironment parameters. The detection of CTCs may therefore be used as an indicator of tumor prognosis.

Available only for authorised users

Amantini C, Morelli MB, Nabissi M et al (2019) Expression profiling of circulating tumor cells in pancreatic ductal adenocarcinoma patients: biomarkers predicting overall survival. Front Oncol 9:874CrossRefPubMedPubMedCentral

Guan Y, Xu F, Tian J et al (2020) Pathology of circulating tumor cells and the available capture tools (review). Oncol Rep 43(5):1355–1364PubMed

Danese E, Montagnana M, Lippi G (2019) Circulating molecular biomarkers for screening or early diagnosis of colorectal cancer: which is ready for prime time? Ann Transl Med 7(21):610CrossRefPubMedPubMedCentral

Lim SH, Becker TM, Chua W et al (2014) Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol 67(10):848–853CrossRefPubMed

Yu M, Bardia A, Wittner BS et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584CrossRefPubMedPubMedCentral

Jayachandran J, Srinivasan H, Mani KP (2021) Molecular mechanism involved in epithelial to mesenchymal transition. Arch Biochem Biophys 710:108984CrossRefPubMed

Guan Y, Xu F, Tian J et al (2021) The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma. BMC Cancer 21(1):826CrossRefPubMedPubMedCentral

Cheaito KA, Bahmad HF, Hadadeh O et al (2019) EMT markers in locally-advanced prostate cancer: predicting recurrence? Front Oncol 9:131CrossRefPubMedPubMedCentral

Xie X, Wang L, Wang X et al (2021) Evaluation of cell surface vimentin positive circulating tumor cells as a diagnostic biomarker for lung cancer. Front Oncol 11:672687CrossRefPubMedPubMedCentral

10.

Lee JS, Magbanua MJM, Park JW (2016) Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat 160(3):411–424CrossRefPubMed

11.

Satelli A, Batth IS, Brownlee Z et al (2016) Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep 6:28910CrossRefPubMedPubMedCentral

12.

van Buuren S, Groothuis-Oudshoorn K (2011) mice: multivariate imputation by chained equations in R. J Stat Softw 45(3):1–67CrossRef

13.

Hinz S, Hendricks A, Wittig A et al (2017) Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients—a prospective study. BMC Cancer 17(1):53CrossRefPubMedPubMedCentral

14.

Di Meo A, Bartlett J, Cheng Y et al (2017) Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer 16(1):80CrossRefPubMedPubMedCentral

15.

Lianidou ES, Mavroudis D, Pantel K (2013) Advances in circulating tumor cells (ACTC): from basic research to clinical practice. Breast Cancer Res 15(6):319CrossRefPubMedPubMedCentral

16.

Huang X, Gao P, Song Y et al (2015) Meta-analysis of the prognostic value of circulating tumor cells detected with the cell search system in colorectal cancer. BMC Cancer 15:202CrossRefPubMedPubMedCentral

17.

Delgado-Ureña M, Ortega FG, de Miguel-Pérez D (2018) Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. J Transl Med 16(1):251CrossRefPubMedPubMedCentral

18.

Hattori M, Nakanishi H, Yoshimura M et al (2019) Circulating tumor cells detection in tumor draining vein of breast cancer patients. Sci Rep 9(1):18195CrossRefPubMedPubMedCentral

19.

de Kruijff IE, Sieuwerts AM, Onstenk W et al (2019) Circulating tumor cell enumeration and characterization in metastatic castration-resistant prostate cancer patients treated with cabazitaxel. Cancers (Basel). https://doi.org/10.3390/cancers11081212CrossRefPubMed

20.

Huang X, Gao P, Song Y et al (2014) Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer 14:976CrossRefPubMedPubMedCentral

21.

Wallwiener M, Riethdorf S, Hartkopf AD et al (2014) Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer 14:512CrossRefPubMedPubMedCentral

22.

Borowski DW, Banky B, Banerjee AK et al (2014) Intra-arterial methylene blue injection into ex vivo colorectal cancer specimens improves lymph node staging accuracy: a randomized controlled trial. Colorectal Dis 16(9):681–689CrossRefPubMed

23.

Patenaude A, Parker J, Karsan A (2010) Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res 79(3):217–223CrossRefPubMed

24.

Bidard FC, Huguet F, Louvet C et al (2013) Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol 24(8):2057–2061CrossRefPubMed

25.

Gu T, Ren J, Hu Z et al (2022) A predictive model based on liquid biopsy for non-small cell lung cancer to assess patient’s prognosis: development and application. Tissue Cell 77:101854CrossRefPubMed

26.

Tsai WS, Chen JS, Shao HJ et al (2016) Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep 6:24517CrossRefPubMedPubMedCentral

27.

Das A, Kunkel M, Joudeh J et al (2015) Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biol Ther 16(5):709–713CrossRefPubMedPubMedCentral

28.

Ribeiro SM, Braga CB, Peria FM et al (2016) Effect of zinc supplementation on antioxidant defenses and oxidative stress markers in patients undergoing chemotherapy for colorectal cancer: a placebo-controlled, prospective randomized trial. Biol Trace Elem Res 169(1):8–16CrossRefPubMed

29.

Bahnassy AA, Salem SE, Mohanad M et al (2019) Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: a comparative study for four different techniques of detection (flowcytometry, cell search, quantitative real-time PCR and cytomorphology). Exp Mol Pathol 106:90–101CrossRefPubMed

30.

Dizdar L, Fluegen G, Dalum G et al (2019) Detection of circulating tumor cells in colorectal cancer patients using the GILUPI cell collector: results from a prospective, single-center study. Mol Oncol 13(7):1548–1558CrossRefPubMedPubMedCentral

31.

Li Y, Cheng X, Chen Z et al (2017) Circulating tumor cells in peripheral and pulmonary venous blood predict poor long-term survival in resected non-small cell lung cancer patients. Sci Rep 7(1):4971CrossRefPubMedPubMedCentral

32.

Pang S, Li H, Xu S et al (2021) Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer. Sci Rep 11(1):13441CrossRefPubMedPubMedCentral

33.

Zhang D, Zhao L, Zhou P et al (2017) Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Cancer Cell Int 17:6CrossRefPubMedPubMedCentral

34.

Galizia G, Gemei M, Orditura M et al (2013) Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg 17(10):1809–1818CrossRefPubMed

Title: Predictive value of circulating tumor cell counts during the treatment of cancer: interactions with the blood microenvironment
Authors: Liu Yang
Xiaojiao Zeng
Gui Yang
Yirong Li
Yunbao Pan
Publication date: 27-05-2023
Publisher: Springer Nature Singapore
Keywords: Cancer Biomarker
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 8/2023
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-023-02355-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2023

Association between human papillomavirus and oral cancer: a literature review

Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors

Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study

Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body

Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer